^
    2years
    Biomarkers related to survival benefit in the treatment of metastatic luminal breast cancer (mBC) with cyclin 4/6 inhibitors (CDK 4/6i) plus endocrine therapy (ET) (SABCS 2022)
    CONCLUSION Treatment with CDK4/6i plus ET achieved long treatment duration in patients with low expression of cyclin E (OR 3,1 p:0,045), positive progesterone receptor (OR 3,89 p: 0023) and specially in patients with positive progesterone receptor and low expression of cyclin E (OR 7,22 p:0,016 ). Patients with negative progesterone receptor and high expression of cyclin E had a poor prognosis with a median disease-free survival of 6 months (2.8 – 9.2), so these patients required other treatment approaches to improve their outcomes.
    PGR (Progesterone receptor) • CDK4 (Cyclin-dependent kinase 4)
    |
    PGR expression • PGR overexpression • CCNE1 underexpression
    over4years
    [VIRTUAL] Targeting the metabolic-epigenetic axis to sensitize HR-proficient ovarian cancer to PARP inhibitors (AACR-II 2020)
    Together, our data suggest that wtIDH1-mediated metabolism affects the epigenome in cyclin E1-high cells, which contributes to both fallopian tube transformation and HR-proficiency. Targeting wtIDH1 with current FDA-approved inhibitors may therefore be a rational therapeutic strategy for cyclin E1-high ovarian cancer patients.
    BRCA Biomarker • PARP Biomarker
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • CCNE1 (Cyclin E1) • RAD51 (RAD51 Homolog A)
    |
    CCNE1 overexpression • CCNE1 expression • CCNE1 underexpression